Drug Combinations

"Drug Combinations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.

Descriptor ID	D004338
MeSH Number(s)	D26.310
Concept/Terms	Drug Combinations Drug Combinations Combinations, Drug

Below are MeSH descriptors whose meaning is more general than "Drug Combinations".

Chemicals and Drugs [D]
Pharmaceutical Preparations [D26]
Drug Combinations [D26.310]

Below are MeSH descriptors whose meaning is more specific than "Drug Combinations".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Combinations" by people in this website by year, and whether "Drug Combinations" was a major or minor topic of these publications.

Bar chart showing 80 publications over 28 distinct years, with a maximum of 7 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
1997	0	1	1
1998	0	1	1
1999	0	1	1
2000	0	1	1
2001	0	1	1
2002	0	4	4
2003	0	5	5
2004	0	5	5
2005	0	3	3
2006	0	3	3
2007	0	5	5
2008	0	5	5
2009	0	5	5
2010	0	2	2
2011	0	7	7
2012	0	3	3
2013	0	2	2
2014	0	3	3
2015	1	3	4
2016	0	3	3
2017	0	5	5
2018	0	2	2
2019	1	1	2
2020	1	1	2
2021	0	2	2
2023	0	1	1
2024	1	0	1

Below are the most recent publications written about "Drug Combinations" by people in Profiles.

Roche-Lima A, Rosado-Qui?ones AM, Feliu-Maldonado RA, Figueroa-Gispert MDM, D?az-Rivera J, D?az-Gonz?lez RG, Carrasquillo-Carrion K, Nieves BG, Col?n-Lorenzo EE, Serrano AE. Antimalarial Drug Combination Predictions Using the Machine Learning Synergy Predictor (MLSyPred?) tool. Acta Parasitol. 2024 Mar; 69(1):415-425.

View in: PubMed
Peat TJ, Gaikwad SM, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, Phyo Z, Andres M, Hughitt VK, Simpson RM, Miller MA, Girvin AT, Taylor A, Williams D, D'Antonio N, Zhang Y, Rajagopalan A, Flietner E, Wilson K, Zhang X, Shinn P, Klumpp-Thomas C, McKnight C, Itkin Z, Chen L, Kazandijian D, Zhang J, Michalowski AM, Simmons JK, Keats J, Thomas CJ, Mock BA. Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma. Cancer Lett. 2023 08 01; 568:216284.

View in: PubMed
Triebwasser MP, Barrett DM, Bassiri H, Bunin N, Elgarten C, Freedman J, Geera AS, Monos D, Lambert MP, Olson T, Seif AE, Paessler M, Petrosa W, Reilly AF, Romberg N, Sullivan KE, Quinn GZ, Behrens E, Teachey DT. Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatr Blood Cancer. 2021 07; 68(7):e29026.

View in: PubMed
Liang D, Ma J, Wei B. Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness. Sci Rep. 2021 01 28; 11(1):2605.

View in: PubMed
Ahmad S, He Q, Williams KP, Scott JE. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach. SLAS Discov. 2020 09; 25(8):923-938.

View in: PubMed
Roshandel G, Kamangar F, Marshall T, Cheng KK, Hemming K, Malekzadeh R. Polypill for prevention of cardiovascular diseases - Authors' reply. Lancet. 2020 02 08; 395(10222):414-415.

View in: PubMed
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019 08 24; 394(10199):672-683.

View in: PubMed
Sowunmi A, Ntadom G, Akano K, Ibironke FO, Ayede AI, Agomo C, Folarin OA, Gbotosho GO, Happi C, Oguche S, Okafor HU, Meremikwu M, Agomo P, Ogala W, Watila I, Mokuolu O, Finomo F, Ebenebe JC, Jiya N, Ambe J, Wammanda R, Emechebe G, Oyibo W, Useh F, Aderoyeje T, Dokunmu TM, Alebiosu OT, Amoo S, Basorun OK, Wewe OA, Okafor C, Akpoborie O, Fatunmbi B, Adewoye EO, Ezeigwe NM, Oduola A. Declining responsiveness of childhood Plasmodium falciparum infections to artemisinin-based combination treatments ten years following deployment as first-line antimalarials in Nigeria. Infect Dis Poverty. 2019 Aug 06; 8(1):69.

View in: PubMed
Rathinavelu A, Kanagasabai T, Dhandayuthapani S, Alhazzani K. Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models. Oncol Rep. 2018 Apr; 39(4):1711-1724.

View in: PubMed
Hernandez G, Zhao L, Franke AA, Chen YL, Mack WJ, Brinton RD, Schneider LS. Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ?-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause. 2018 02; 25(2):191-196.

View in: PubMed

People

Explore

Similar Concepts

Top Journals